UNITED STATES: RQM+, a leading global MedTech contract research organization (CRO), has announced the appointment of John Potthoff, Ph.D., as its new CEO. This transition follows Margaret Keegan’s decision to step back from day-to-day operations to focus on her role as an operating partner with Linden Capital Partners, while remaining on RQM+’s board.
John Potthoff, co-founder and former CEO of Elligo Health Research, brings extensive expertise in the MedTech industry to his new role. With previous leadership positions at companies such as Theorem Clinical Research and INC Research, Potthoff is well-equipped to drive RQM+’s growth and advance global healthcare through MedTech innovation.
Also Read: RMS Cloud Appoints David Murray as CEO to Lead Global Expansion Efforts
“During Margaret’s tenure, she completed three acquisitions and made significant progress in creating an end-to-end MedTech CRO at RQM+,” said Potthoff. “I look forward to building on this remarkable foundation and continuing to drive growth and advance global healthcare through MedTech innovation.”
Margaret Keegan expressed her confidence in Potthoff’s leadership, stating, “I am extremely proud of the RQM+ team’s many accomplishments. While I’ll be stepping away from day-to-day operations, I look forward to continuing to support the company. I believe John is a proven leader and is very knowledgeable about the company and our industry. He is well-positioned to lead and enhance RQM+ to meet the ever-changing MedTech industry needs now and into the future.”
Embracing Leadership Change at RQM+
Potthoff, in a LinkedIn post, expressed his excitement about his new role, stating, “Today marks an exciting change in my career stepping into the role of CEO at RQM+. I have served on the RQM+ board since 2021, so not only do I know the team and business, but also this is a great fit for my experience growing organizations and with my MedTech industry background.”
RQM+ stands as a prominent figure in the MedTech sector, providing a comprehensive range of services including consulting, clinical trials, lab operations, reimbursement services, and technology solutions tailored to support the entirety of the product lifecycle.
Backed by a diverse global team comprising clinical, technical, and industry specialists, RQM+ endeavors to redefine standards of excellence within the industry. Their efforts focus on mitigating commercialization risks associated with medical devices, digital therapeutics, and diagnostics, thus fostering innovation in healthcare. Enjoying the trust of leading medical device manufacturers and in vitro diagnostic (IVD) companies alike, RQM+ remains steadfast in its commitment to advancing healthcare through cutting-edge solutions and practices.
Also Read: ASML’s New CEO Christophe Fouquet Takes Charge Amidst Geopolitical Tensions
